Robert Richard, MD
Neurology · Reston, VANPI 1750350989
Payments from drug & device makers
Across 307 payments — averaging $13.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$997
- AbbVie$863
- Harmony Biosciences LLC$292
- Jazz Pharmaceuticals Inc.$244
- Lundbeck LLC$194
- Pfizer$143
- plus $1K from 31 others
What the payments were for
- Speaking & faculty fees$140%
- Food & beverage$3,97999%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 151 | $997 |
| AbbVie(2 entities) | 56 | $863 |
| Harmony Biosciences LLC | 13 | $292 |
| Jazz Pharmaceuticals Inc. | 9 | $244 |
| Lundbeck LLC | 10 | $194 |
| Pfizer | 8 | $143 |
| Axsome Therapeutics, Inc. | 5 | $109 |
| Merz Pharmaceuticals, LLC | 4 | $96 |
| Lilly USA, LLC | 5 | $94 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $86 |
| Argenx US, Inc. | 3 | $71 |
| Novartis | 4 | $69 |
| Supernus Pharmaceuticals, Inc. | 3 | $69 |
| Eisai Inc. | 3 | $64 |
| Vanda Pharmaceuticals Inc. | 4 | $59 |
| UCB, Inc. | 2 | $47 |
| AstraZeneca(2 entities) | 2 | $44 |
| Revance Therapeutics, Inc. | 1 | $39 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| ZOLL Respicardia, Inc. | 2 | $33 |
| Upsher-smith Laboratories LLC | 1 | $31 |
| Tanabe Pharma America, Inc. | 1 | $29 |
| TG Therapeutics, Inc. | 1 | $28 |
| Noctrix Health, Inc. | 1 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Amgen | 2 | $24 |
| Cycle Pharmaceuticals Inc | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Bristol Myers Squibb | 1 | $16 |
| Biogen | 1 | $15 |
| Shionogi Inc | 1 | $15 |
| EMD Serono, Inc. | 1 | $14 |
| Acorda Therapeutics, Inc | 1 | $14 |
How this compares
$4,004 in reported general payments places this provider in the 60th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 11 | $312,082 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 12 | $99,371 |
| ImitrexSumatriptan Succinate | 11 | $87,265 |
| UbrelvyUbrogepant | 19 | $50,604 |
| Emgality PenGalcanezumab-Gnlm | 28 | $43,573 |
| Aimovig AutoinjectorErenumab-Aooe | 32 | $38,190 |
| Nurtec OdtRimegepant Sulfate | 31 | $32,055 |
| ZonegranZonisamide | 11 | $30,901 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 26 | $27,432 |
| QuliptaAtogepant | 17 | $21,079 |
| Rivastigmine | 85 | $20,712 |
| Memantine Hcl ErMemantine Hcl | 142 | $18,983 |
| Lamotrigine ErLamotrigine | 18 | $7,647 |
| Memantine Hcl | 158 | $5,782 |
| Tegretol XrCarbamazepine | 14 | $5,416 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPanzyga, Nurtec Odt | $143 | $131,42543 claims |
| AbbVieUbrelvy, Qulipta | $863 | $71,68436 claims |
| Upsher-smith Laboratories LLCTopiramate | $31 | $98445 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 474 neurology providers in Virginia.
Other neurology in Reston
- Michelle BetzVirginia Beach$3.3M
- Daniel CohenNorfolk$2.9M
- Heidi CraytonVienna$2.5M
- Ramsey FalconerAlexandria$2.4M
- Robert ShinCharlottesville$2.2M
- Simon FishmanAlexandria$1.6M
- Ingrid Loma MillerNorfolk$1.2M
- Matthew BarrettHenrico$1.1M
- James BickselMc Lean$1M
- Rahul DaveFairfax$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.